-
Signature
-
/s/ James B. Bucher, attorney-in-fact for Vincent Vultaggio
-
Issuer symbol
-
ZNTL
-
Transactions as of
-
02 Feb 2026
-
Net transactions value
-
-$7,875
-
Form type
-
4
-
Filing time
-
04 Feb 2026, 20:27:50 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Vultaggio Vincent |
PAO and PFO |
C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO |
/s/ James B. Bucher, attorney-in-fact for Vincent Vultaggio |
04 Feb 2026 |
0002018766 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ZNTL |
Common Stock |
Sale |
$6,477 |
-2,540 |
-1.3% |
$2.55 |
187,286 |
02 Feb 2026 |
Direct |
F1 |
| transaction |
ZNTL |
Common Stock |
Sale |
$1,398 |
-556 |
-0.3% |
$2.52 |
186,730 |
03 Feb 2026 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: